Genmab appoints Judith Klimovsky as Chief Development Officer
The biotechnology company Genmab announced today the appointment of Judith Klimovsky, MD, as Executive Vice President and Chief Development Officer.
Dr Klimovsky will lead the company’s global product development activities and will join the Executive team of CEO, Dr Jan van de Winkel and CFO, David Eatwell.
Dr Klimovsky will be responsible for Genmab’s product development strategy in line with the company’s corporate strategy and the 2025 Vision. Dr Klimovsky has had a distinguished career in drug development, most recently serving as Senior Vice President and Global Head, Oncology Clinical Development, at Novartis. She is a haematologist by training with extensive experience in various roles at BMS, MSD and Novartis, as well as having experience in haematology clinical practice.
Dr Klimovsky has broad expertise in Phase I-IV drug development and in medical affairs. She has strong leadership skills and has been instrumental in the development of several key cancer drugs.
“We are very pleased to welcome Judith to Genmab. She has a strong track record and skills in cancer drug development” said Jan van de Winkel, PhD, CEO of Genmab.
“I am very much looking forward to joining Genmab at this exciting time in the company’s development. Having watched Genmab’s development in recent years, I have been impressed by the company’s science-based approach, world-class antibody skills, robust product pipeline and competencies in drug development, and I’m eager to start working with the team and state-of-the art portfolio,” said Dr Judith Klimovsky, new Chief Development Officer at Genmab.